Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389272 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| SCHEMBL5489936 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| Silver SCHEMBL11460244 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| SCHEMBL5487129 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| SCHEMBL19348563 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| SCHEMBL957639 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| SCHEMBL5487493 | 0.95 | HTT (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| SCHEMBL17332127 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| SCHEMBL19348554 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT | |
| Potassium Ion SCHEMBL5492277 | 0.95 | HSD11B1 (0.45) | HSD11B1L3MBTL1EPHX1EPHX2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192875-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10584109-B2 | Processes for preparing antiviral compounds | Gillead Pharmasset LLC (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2018-06-28 | — | — | US | disclosed |
| US-9890134-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670187-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3154984-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015191437-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-8952204-B2 | Sulfonium salt, method for producing the same, and photoacid generator | DSP GOKYO FOOD & CHEMICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140163254-A1 | NOVEL SULFONIUM SALT, METHOD FOR PRODUCING THE SAME, AND PHOTOACID GENERATOR | MP GOKYO FOOD & CHEMICAL CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-20070037909-A1 | Diamondoid-based nucleating agents for thermoplastics | CHEVRON U.S.A. INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584109-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | HSD11B1 2902/4885L3MBTL1 4079/4885EPHX1 2160/4885 |
| US-11192875-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | HSD11B1 2902/4885L3MBTL1 4079/4885EPHX1 2160/4885 |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | HSD11B1 2902/4885L3MBTL1 4079/4885EPHX1 2160/4885 |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | HSD11B1 2902/4885L3MBTL1 4079/4885EPHX1 2160/4885 |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | HSD11B1 2902/4885L3MBTL1 4079/4885EPHX1 2160/4885 |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | HSD11B1 2902/4885L3MBTL1 4079/4885EPHX1 2160/4885 |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | HSD11B1 2902/4885L3MBTL1 4079/4885EPHX1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.